Tamrisa is a specialized pharma company dedicated to tackling anti-microbial resistance through Innovation, Stewardship and Access. It aims to provide a novel, comprehensive, ambitious and sustainable response to AMR threat, in line with the guidelines set by World Health Organization.

As for Innovation, Tamrisa develops new antibiotics against top priority multi-drug resistant pathogens, with a view to reset the clock of AMR. Its Paris-based R&D team currently focuses on the development of two novel chemical entities to treat carbapenem resistant Gram-negative bacterial infections. These two programs – TMR010 and TMR020 – are based on the diazabicyclooctane scaffold that has already demonstrated outstanding stability to hydrolysis by serine- and metallo-beta-lactamases.

Parallel to this Innovation activity supported by REPAIR Impact Fund, Tamrisa is also committed to Access and Stewardship. Tamrisa commercializes proven existing antibiotics, with a view to reinforce their access for patients around the world. Lastly Tamrisa works at creating the conditions required for the appropriate use of antibiotics in human healthcare, and thus contribute to limit resistance expansion to both existing and future molecules.